Bristol-Myers Squibb’s daclatasvir, asunaprevir and beclabuvir cured high rates of hepatitis C virus (HCV) among those with genotype 1 without cirrhosis. Publishing their findings in the Journal of the American Medical Association, researchers in the UNITY-1 trial treated 312 treatment-naive and 103 treatment-experienced people with hep C with 12 weeks of the pan-genotypic NS5A inhibitor daclatasvir, the NS3 protease inhibitor asunaprevir, and the non-nucleoside NS5B inhibitor beclabuvir.

Overall, 91.3 percent (379 of 415) of the participants achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). This included 92 percent (287 of 312) of the treatment-naive participants and 89.3 percent (92 of 103) of the treatment-experienced participants.

The most common side effects were headache, fatigue, diarrhea and nausea.

To read the study abstracts, click here.
To read a press release on the study, click here.